Next Article in Journal
Health-Related Quality of Life, Family Conflicts and Fear of Injecting: Perception Differences between Preadolescents and Adolescents with Type 1 Diabetes and Their Mothers
Previous Article in Journal
The Basic Psychological Needs in the Classroom Scale (BPN-CS)
Previous Article in Special Issue
Repetitive Transcranial Magnetic Stimulation: A Potential Treatment for Obesity in Patients with Schizophrenia
Review

Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside

by 1,2,3
1
Spring Valley Hospital and Medical Center, Valley Health System, Las Vegas, NV 89118, USA
2
Department of Psychiatry, University of Nevada, Las Vegas, NV 89154, USA
3
College of Osteopathic Medicine, Touro University Nevada, Las Vegas, NV 89014, USA
Academic Editor: Valentina Echeverria
Received: 13 May 2021 / Revised: 12 June 2021 / Accepted: 23 June 2021 / Published: 30 June 2021
There is growing research interest in learning the genetic basis of response and adverse effects with psychotropic medications, including antipsychotic drugs. However, the clinical utility of information from genetic studies is compromised by their controversial results, primarily due to relatively small effect and sample sizes. Clinical, demographic, and environmental differences in patient cohorts further explain the lack of consistent results from these genetic studies. Furthermore, the availability of psychopharmacological expertise in interpreting clinically meaningful results from genetic assays has been a challenge, one that often results in suboptimal use of genetic testing in clinical practice. These limitations explain the difficulties in the translation of psychopharmacological research in pharmacogenetics and pharmacogenomics from bench to bedside to manage increasingly treatment-refractory psychiatric disorders, especially schizophrenia. Although these shortcomings question the utility of genetic testing in the general population, the commercially available genetic assays are being increasingly utilized to optimize the effectiveness of psychotropic medications in the treatment-refractory patient population, including schizophrenia. In this context, patients with treatment-refractory schizophrenia are among of the most vulnerable patients to be exposed to the debilitating adverse effects from often irrational and high-dose antipsychotic polypharmacy without clinically meaningful benefits. The primary objective of this comprehensive review is to analyze and interpret replicated findings from the genetic studies to identify specific genetic biomarkers that could be utilized to enhance antipsychotic efficacy and tolerability in the treatment-refractory schizophrenia population. View Full-Text
Keywords: genetic testing; antipsychotic; pharmacotherapy; schizophrenia genetic testing; antipsychotic; pharmacotherapy; schizophrenia
MDPI and ACS Style

Shad, M.U. Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside. Behav. Sci. 2021, 11, 97. https://0-doi-org.brum.beds.ac.uk/10.3390/bs11070097

AMA Style

Shad MU. Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside. Behavioral Sciences. 2021; 11(7):97. https://0-doi-org.brum.beds.ac.uk/10.3390/bs11070097

Chicago/Turabian Style

Shad, Mujeeb U. 2021. "Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside" Behavioral Sciences 11, no. 7: 97. https://0-doi-org.brum.beds.ac.uk/10.3390/bs11070097

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop